Welcome to our dedicated page for SOLESENCE SEC filings (Ticker: SLSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SOLESENCE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SOLESENCE's regulatory disclosures and financial reporting.
Solésence, Inc., through its wholly owned subsidiary Solésence, LLC, entered into a Settlement Agreement and Release with Refy Beauty Ltd to resolve disputes over certain consumer care products previously sold to Refy. Solésence agreed to pay Refy the British Pound Sterling equivalent of $938,000 in twelve equal installments of $78,166.66, with the first payment due on August 5, 2026 and each subsequent payment due 30 days later. The parties also agreed to a six month exclusivity period for development of a new SPF product and potential negotiation of a new supply agreement. If a new supply agreement is executed, the final six scheduled installment payments would instead be credited toward purchases of the SPF product under that supply agreement.
Solésence, Inc. reported a net loss for the quarter ended March 31, 2026 as revenue declined. Total revenue was $12,957 (in thousands), down from $14,625 (in thousands) a year earlier, driven by lower consumer products and advanced materials sales, partly offset by higher personal care ingredients revenue.
Gross profit was $3,337 (in thousands), roughly flat versus $3,382 (in thousands), but higher selling, general and administrative expenses of $2,799 (in thousands) and research and development of $1,042 (in thousands) contributed to a net loss of $766 (in thousands), compared with net income of $80 (in thousands) in 2025.
Operating cash flow improved to $1,517 (in thousands) from a use of $7,221 (in thousands), aided by working capital changes. Cash decreased to $573 (in thousands) as of March 31, 2026, while related-party borrowings remained significant, including a $9,500 (in thousands) inventory facility and $3,047 (in thousands) drawn on an accounts receivable line.
Solésence, Inc. reported first quarter 2026 revenue of $13.0 million, down from $14.6 million a year earlier, as it invested in its Transform and Transcend operational initiative. Despite lower sales, gross profit was $3.3 million and gross margin improved to 26% from 23%.
The company posted a net loss of approximately $0.8 million for the quarter, compared with net income of about $0.08 million in 2025, and Adjusted EBITDA declined to $(0.1) million from $0.6 million. Management highlighted near-term profitability pressure from training and organizational restructuring, but expects efficiency gains and lower labor costs to support better results later in the year.
Solésence, Inc. announced that its Board of Directors appointed Marc James as a Class II independent director, effective April 24, 2026. He will serve for the remainder of the Class II term, ending at the 2026 Annual Meeting of Shareholders.
James joins the Board’s Audit and Finance, Compensation, and Nominating and Corporate Governance Committees. The company highlights his capital markets and strategic experience as support for its Transform & Transcend strategic initiative and long-term growth objectives.
Solésence, Inc. filed Amendment No. 1 to its annual report to add Exhibit 97.1, which was inadvertently omitted from the original filing. The company states that no other items are being revised and the amendment does not reflect events after the original report.
The aggregate market value of voting stock held by non‑affiliates was $27,254,231 as of June 30, 2025, and 70,632,445 common shares were outstanding as of March 30, 2026. The filing also lists numerous previously filed material contracts, loan agreements, employment agreements, and the Solésence 2025 Equity Compensation Plan as exhibits.
Solésence, Inc. reports strong 2025 growth as it advances its rebranding from Nanophase Technologies into a skin-health focused consumer products company. Total revenue rose to $62,064, driven mainly by prestige beauty consumer products built on its Active Stress Defense™ technology and mineral-based UV protection APIs.
The company increasingly prioritizes finished “white label” and custom skin-care products over legacy advanced materials, operates two FDA-registered, ISO-certified facilities near Chicago, and invests heavily in R&D and capacity to meet what management describes as unprecedented demand from brand partners.
Solésence, Inc. reported record full-year 2025 revenue of $62.1 million, up 19% from $52.3 million, as it expanded its SPF-infused beauty product portfolio. Despite higher sales, full-year gross margin fell to 26% from 31% and net income declined to $1.8 million from $4.2 million, reflecting higher operating costs.
In the fourth quarter, revenue was $12.5 million, roughly flat year over year, but gross margin improved to 27% from 22%, turning a net loss of $0.6 million in 2024’s quarter into net income of $0.2 million. The company highlighted its “Transform & Transcend” initiative, aimed at operational excellence, technology-driven market expansion, service model innovation, and global growth with brand partners, alongside adding 20 new brand partners and securing 16 new patents.
Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer. Under the agreement, effective December 2, 2025, Jankowski will receive severance pay totaling $366,912, accelerated vesting of all his outstanding stock options, and continued company-paid health insurance premiums under COBRA for the duration of the severance period. In return, he is providing a broad release of claims against the company and reaffirming obligations such as restrictive covenants and assistance in certain potential disputes. The separation agreement is filed as an exhibit to this report, with some portions redacted as confidential.
Solésence, Inc. filed a Form 8‑K to furnish information under Item 2.02 (Results of Operations and Financial Condition). The company reported that it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference.
The filing also includes a “Solésence Third Quarter 2025 Conference Call Script” as Exhibit 99.2. These materials provide the company’s communications around its quarterly results, with the exhibits serving as the official source documents.
Solésence, Inc. reported Q3 2025 results with total revenue of $14,597, down from $16,866 a year ago, and a net loss of $1,120 versus prior-year income of $3,045. Gross profit was $3,370 compared with $6,102 as cost of revenue rose to $11,227. Selling, general and administrative expense increased to $3,069, reflecting higher legal, credit loss allowance, employee and NASDAQ uplisting costs.
For the nine months, revenue reached $49,581, up from $39,780, and net income was $1,627 versus $4,793. Cash was $429 at quarter end, with operating cash outflow of $10,386 and financing inflows of $11,099, including related-party credit facilities. Accounts receivable, net, increased to $9,709 and the allowance for credit losses to $1,729. Three customers represented 60% of Q3 revenue.
Other items included recognition of $1,234 from the Employee Retention Credit and $194 of related interest. A confidential settlement provides for a $675 payment to Solésence by January 15, 2026. The company also notes BASF supply agreement contingencies that could impact equipment and revenue if triggered.